PharmaPoint: Parkinsons Disease - US Drug Forecast and Market Analysis, Key Trends, Demand, Forecast, Opportunities to 2022

ResearchMoz added Latest Research Report titled " PharmaPoint: Parkinsons Disease - US Drug Forecast and Market Analysis to 2022 " to it's Large Report database.

PharmaPoint: Parkinsons Disease - US Drug Forecast and Market Analysis to 2022

Summary

Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=197508

This market is expected to grow faster than any other market, including the 5EU, due in part to the introduction of two brands already in use in the 5EU, Neupro and Duodopa, launched in the US at the beginning of the forecast in 2012 and 2014, respectively. Other factors responsible for growth in this market are an aging population that contributes to an increased prevalence of Parkinsons disease in the US and the launch of six new pipeline agents (in addition to Duodopa and Neupro).

Scope

- Overview of Parkinsons Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Parkinsons Disease market.

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Content
.
.
.
lines and Leading Prescribed Drugs 26
4.2 Treatment Synopsis 27
4.2.1 Dopaminergic Therapy Classes 28
4.2.2 Treatment of Parkinsons disease by Stage 30
4.2.3 Other Treatment Options 33
4.3 Parkinsons Disease Assessment Scales 33
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 34
4.3.2 Hoehn and Yahr Clinical Staging 36
4.3.3 Other Clinical Assessments 37
4.4 Diagnosis and Treatment of Parkinsons Disease by Country 37
4.4.1 US 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Strategic Competitor Assessment 42
5.3 Product Profiles - Levodopa Combination Therapy 43
5.3.1 Sinemet (carbidopa/levodopa) 44
5.3.2 Duodopa (carbidopa/levodopa intestinal gel) 48
5.4 Product Profiles - COMT Inhibitors 52
5.4.1 Stalevo/Comtan (entacapone) 52
5.5 Dopamine Agonists 57
5.5.1 Neupro (rotigotine transdermal patch) 58
5.5.2 Requip/Requip XL (ropinirole) 64
5.5.3 Apokyn (apomorphine) 68

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/

This release was published on openPR.